Literature DB >> 16531624

Non-epilepsy uses of antiepilepsy drugs.

Paweł D Zaremba1, Magdalena Białek, Barbara Błaszczyk, Piotr Cioczek, Stanisław J Czuczwar.   

Abstract

Antiepileptic drugs (AEDs) affect various neurotransmitters (i.e. GABA, glutamate), receptors (i.e. GABAergic, glutamatergic), and ion channels (i.e. for sodium or calcium) which is responsible for their anticonvulsant activity. However, this broad spectrum of action may be also utilized in other pathological conditions. For example, both conventional and newer AEDs may be used in patients suffering from neuropathic pain, migraine, essential tremor, spasticity, restless legs syndrome and a number of psychiatric disorders (f.e. bipolar disease or schizophrenia). Also, isolated data point to their potential use in Parkinson's or Alzheimer's disease. There is experimental background indicating a potent neuroprotective efficacy of AEDs in numerous models of brain ischemia. However, the clinical data are very limited and this problem requires careful assessment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531624

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  10 in total

1.  A comparative study of excitatory and inhibitory amino acids in three different brainstem nuclei.

Authors:  Waleed M Renno; Moussa Alkhalaf; Alyaa Mousa; Reem A Kanaan
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

2.  Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).

Authors:  David F McComsey; Virginia L Smith-Swintosky; Michael H Parker; Douglas E Brenneman; Ewa Malatynska; H Steve White; Brian D Klein; Karen S Wilcox; Michael E Milewski; Mark Herb; Michael F A Finley; Yi Liu; Mary Lou Lubin; Ning Qin; Allen B Reitz; Bruce E Maryanoff
Journal:  J Med Chem       Date:  2013-11-11       Impact factor: 7.446

Review 3.  Influence of pharmacological and epigenetic factors to suppress neurotrophic factors and enhance neural plasticity in stress and mood disorders.

Authors:  Shashikanta Tarai; Rupsha Mukherjee; Sharda Gupta; Albert A Rizvanov; Andras Palotás; V S Chandrasekhar Pammi; Arindam Bit
Journal:  Cogn Neurodyn       Date:  2019-02-01       Impact factor: 5.082

4.  Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients.

Authors:  Barbara Błaszczyk; Stanisław J Czuczwar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

Review 5.  Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy.

Authors:  Cecilie Johannessen Landmark
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies.

Authors:  Alessandra Vanotti; Maurizio Osio; Enrico Mailland; Caterina Nascimbene; Elisa Capiluppi; Claudio Mariani
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Concomitant medication of psychoses in a lifetime perspective.

Authors:  Maria Vares; Peter Saetre; Pontus Strålin; Sten Levander; Eva Lindström; Erik G Jönsson
Journal:  Hum Psychopharmacol       Date:  2011-06-22       Impact factor: 1.672

8.  Use of antiepileptic drugs for hyperkinetic movement disorders.

Authors:  A Siniscalchi; L Gallelli; G De Sarro
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

9.  Clinical utility of adjunctive retigabine in partial onset seizures in adults.

Authors:  Konrad Rejdak; Jarogniew J Luszczki; Barbara Błaszczyk; Roman Chwedorowicz; Stanislaw J Czuczwar
Journal:  Ther Clin Risk Manag       Date:  2012-01-20       Impact factor: 2.423

10.  Role of vitamin D3 in treatment of lumbar disc herniation--pain and sensory aspects: study protocol for a randomized controlled trial.

Authors:  Mahsa Sedighi; Ali Haghnegahdar
Journal:  Trials       Date:  2014-09-25       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.